A previous study reported that the combination treatment of SGLT2i (dapagliflozin) and DPP-4i (saxagliptin) reduced the activation of the NLRP3 inflammasome and delayed DKD progression in mice with type 2 diabetes [45]. This evidence concerns the gene NLRP3 and diabetic kidney disease.